RCS - Yourgene Health PLC - DPYD screening recommended in Spain

Yourgene HealthAnnouncement

18/11/2021 07:05

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211118:nRSR7504Sa&default-theme=true

RNS Number : 7504S  Yourgene Health PLC  18 November 2021

 

Yourgene Health plc

("Yourgene" or the "Company")

 

DPYD screening recommended in Spain

Follows recommendations in Germany, Wales, England and Belgium

 

Manchester, UK - 18 November 2021: Yourgene (AIM: YGEN), a leading
international molecular diagnostics group, welcomes the publication in
Clinical and Translational Oncology, titled: 'Consensus of experts
from the Spanish Pharmacogenetics and Pharmacogenomics Society
and the Spanish Society of Medical Oncology for the genotyping of DPYD
in cancer patients who are candidates for treatment
with fuoropyrimidines(1)', which highlights the benefits of using a DPYD
genotyping test to help identify cancer patients with Dihydropyrimidine
Dehydrogenase (DPD) deficiency prior to treatment with the chemotherapeutic
drug 5-Fluorouracil (5-FU).

 

5-FU is a widely used chemotherapy agent in the treatment of cancers, however
for some patients who suffer from DPD deficiency 5-FU administered at normal
therapeutic doses can cause severe and sometimes lethal side effects. This
review is welcomed by Yourgene as representatives of the Spanish
Pharmacogenetics and Pharmacogenomics Society ('SEFF') and the Spanish Society
of Medical Oncology ('SEOM'), provided the consensus opinion that: "in the
current era of personalized medicine, it is highly recommended to genotype
DPYD polymorphisms before administering fuoropyrimidines."

 

Yourgene launched the Elucigene® DPYD assay, used to detect the four most
clinically relevant DPYD mutations, back in September 2019, and has already
welcomed the screening recommendations in Germany, Wales, NHS England and
Belgium. An estimated two million people globally are treated with
fluoropyrimidines (including 5-FU) each year(2), with between 10-30% of these
patients suffering severe side effects associated with DPD deficiency(3).
The screening enables clinicians to reduce the risk of increased toxicity
from 5-FU exposure in these patients by treatment with a lower dose, or
alternate drug therapy where indicated.

 

Lyn Rees, CEO of Yourgene, commented: "We are thrilled to see DPYD screening
recognised once again, this time in Spain by representatives of SEFF and SEOM.
We look forward to working closely with our established distribution partner
in the region, Diagnostica Longwood, to support DPYD screening across labs in
Spain. By looking at how genes impact upon a patient's response to drugs,
personalised medicine is at the forefront of our healthcare systems more than
ever before, and we are pleased Yourgene is supporting this progression within
the oncology market."

 

References:

1 - https://link.springer.com/article/10.1007%2Fs12094-021-02708-4
(https://link.springer.com/article/10.1007%2Fs12094-021-02708-4)

2 -  D. Meulendijks et al./Cancer Treatment Reviews 50 (2016) 23-34

3 -  Cancer Research UK https://bit.ly/2kLn1uT (https://bit.ly/2kLn1uT)

 

 

 Yourgene Health plc                                Tel: +44 (0)161 669 8122

 Lyn Rees, Chief Executive Officer                  investors@yourgene-health.com (mailto:investors@yourgene-health.com)
 Barry Hextall, Chief Financial Officer
 Joanne Cross, Director of Marketing

 Singer Capital Markets (Joint Corporate Broker)    Tel: +44 (0)20 7496 3000
 Aubrey Powell / Tom Salvesen / George Tzimas

 Stifel Nicolaus Europe Limited (Joint Corporate Broker)                                 Tel: +44 (0)20 7710 7600
 Nicholas Moore / Matthew Blawat / Ben Maddison

 Walbrook PR Ltd (Media and Investor Relations)     Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
 Paul McManus / Lianne Applegarth / Alice Woodings  Mob: 07980 541 893 / 07584 391 303 / 07407 804 654

 

About Yourgene Health

 

Yourgene Health is an international molecular diagnostics group which develops
integrated genomic technologies and services enabling precision medicine. The
group works in partnership with global leaders in DNA technology to advance
diagnostic science.

 

Yourgene primarily develops, manufactures, and commercialises simple and
accurate molecular diagnostic solutions, for reproductive health, precision
medicine and now infectious diseases. The Group's flagship products include
non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic
disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests,
and a recent extension into the oncology space with DPYD genotyping.

 

The launch of Yourgene Genomic Services has enabled Yourgene to offer a global
laboratory service network equipped to be a full life-cycle partner for
clinical, research and pharmaceutical organisations to support partners at the
preclinical, clinical, and post-market stages to develop, manufacture, obtain
regulatory approval and commercialise new products and services. In addition,
Yourgene Genomic Services offers an NIPT and high throughput COVID testing
service.

 

In August 2020, Yourgene acquired Coastal Genomics, Inc., a sample preparation
technology company based in Vancouver, Canada, enabling the Company to extend
its offering and IP portfolio in the DNA sample preparation sector. The
acquisition increased Yourgene's geographical penetration into the US and
Canada, supplementing existing coverage in the UK, Europe, MEA and Asia.

 

Yourgene Health is headquartered in Manchester, UK with offices in Taipei,
Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM
market under the ticker "YGEN". For more information visit
www.yourgene-health.com (http://www.yourgene-health.com/) and follow us on
twitter @Yourgene_Health.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFLFEALDLDLIL